AI stock analysis · Biotechnology · Last analyzed Jul 8, 2026
Compass Score
3.0/5
Call
Hold
Price
$12.00
AI Target
$40.70 +239.2%
AI Analyst Summary
Olema Pharmaceuticals is a clinical-stage oncology biotech whose investment thesis rests entirely on the potential of its lead asset, palazestrant, a next-generation oral selective estrogen receptor degrader (SERD) targeting ER+/HER2- breast cancer — a multi-billion dollar addressable market. Analyst conviction is exceptionally strong, with 11 of 12 analysts rating the stock a Buy and a consensus price target of $40.70, implying over 230% upside from current levels, reflecting high expectations for upcoming clinical data readouts. The primary risk is binary clinical trial failure: as a pre-revenue, loss-making company, an adverse data outcome for palazestrant would likely result in severe stock impairment with no earnings floor to provide support.
Catalysts
Pivotal clinical data readout for palazestrant (OP-1250) in the OPERA-01 Phase 3 trial in ER+/HER2- breast cancer — a positive result could serve as a de-risking catalyst and accelerate partnership or NDA filing discussions.
Potential combination therapy data showing palazestrant's efficacy alongside CDK4/6 inhibitors, which could expand the addressable patient population and differentiate it from approved oral SERDs like elacestrant.
Corporate development catalysts including a potential licensing deal, partnership, or collaboration agreement driven by the high analyst confidence and large implied upside, which could provide non-dilutive funding and validate the pipeline.
Fundamentals
PeN/A (loss-making) · 1.0/5
Company is pre-profitability with a negative forward P/E of -4.8x and no trailing earnings. Typical for clinical-stage biotech but represents a significant valuation risk without a clear near-term path to profitability.
PegN/A · 3.0/5
PEG ratio is unavailable given the absence of positive earnings. Scored neutral by convention for pre-revenue/pre-profit biotech; pipeline value drives the investment case rather than traditional earnings multiples.
Analyst RatingStrong Buy consensus (1.3) · 5.0/5
11 Buy ratings and 1 Hold with zero Sell ratings across 12 analysts. A consensus of 1.3 reflects exceptionally strong and broad bullish conviction among the analyst community, well above the threshold for a top score.
No meaningful earnings or revenue growth metrics are available, consistent with a clinical-stage biotech. The company is burning cash to fund pipeline development, and EPS losses are expected to persist until a product reaches commercialization.
Price Target Beat2 of 4 quarters · 2.0/5
EPS beat rate of 2 out of the last 4 quarters is below average, suggesting inconsistent execution relative to consensus estimates. For a loss-making biotech, this often reflects variability in R&D spend and cash burn timing.
ManagementMixed execution signals · 3.0/5
Mixed EPS beat history (2 of 4 quarters) tempers confidence, but the near-unanimous analyst bullishness and a consensus target implying over 200% upside suggest the market views management's pipeline strategy favorably. Scored neutral pending clearer clinical milestones.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.